XNAS
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | Q1 2026 | -0.31 | -0.26 | +16.13% | $2.4M | ✅ Beat | +6.83% | +9.64% | — |
| 2026-05-07 | Q1 2026 | -0.31 | -0.26 | +16.13% | $2.4M | ✅ Beat | +1.06% | +13.83% | — |
| 2026-03-05 |
| Q4 2025 |
| -0.32 |
| -0.28 |
| +12.50% |
| $3.9M |
| ✅ Beat |
| -0.33% |
| +10.53% |
| +13.45% |
| 2025-11-12 | Q3 2025 | -0.36 | -0.30 | +16.67% | $2.2M | ✅ Beat | — | — | — |
| 2025-08-12 | Q2 2025 | -0.41 | -0.35 | +14.63% | $2.7M | ✅ Beat | -1.13% | -1.12% | +6.70% |
| 2025-03-10 | Q4 2024 | -0.42 | -0.39 | +7.14% | $2.1M | ✅ Beat | -3.17% | -7.69% | -18.96% |
| 2024-08-06 | Q2 2024 | -0.45 | -0.42 | +6.67% | $3.5M | ✅ Beat | -2.81% | -4.86% | -6.39% |
| 2024-05-07 | Q1 2024 | -0.40 | -0.46 | -15.00% | $2.4M | ❌ Miss | -6.17% | -2.41% | -43.97% |
Showing last 8 quarters.